NewsBenzingaBTIG mantiene la recomendación de compra sobre Zevra Therapeutics y reduce el precio objetivo a 21 dólares. BTIG mantiene la recomendación de compra sobre Zevra Therapeutics y reduce el precio objetivo a 21 dólares. Benzinga 2026.11.13 18:33 (GMT+0) Open on Benzinga Other news Nvidia Shares Rise After Earnings Beat in First Report Since Jensen Huang's Exit NVIDIA Chairman Harvey Jones: Board Has No Intention of Restoring Jensen Huang as CEO Slower Retail Sales Drag on Market SEC reportedly investigating Nvidia amid Huang exit A $3 Billion Reason Why Disney Stock Is in Focus Today Google joins the tech outage trend by announcing it’s not having one